Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Gilles Mees, Mike Sathekge, Alex Maes and Christophe Van de Wiele
Affiliation: University Hospital Ghent, Department of Nuclear Medicine, De Pintelaan 185, 9000-B Ghent, Belgium.
Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence
impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor
phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a
worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given
the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules
have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that
complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how
these tracers can play a role in tomorrows personalized medicine.
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Rights & PermissionsPrintExport